Funding for Faculty

Additional Details

RFP Snapshot: The Siteman Cancer Center (SCC) Biostatistics and Qualitative Research Shared Resource (BQSR) fulfills a critical function by providing methodologic and analytic support for the development and conduct of scientifically sound, innovative cancer research at SCC. Advances in biotechnologies and computing systems/software increasingly require specialized expertise and tools for sophisticated statistical methodologies. Qualitative research requires sound methods and approaches that support rigor and best practice. The overarching goal of the BQSR is to provide a comprehensive, centralized, and accessible biostatistics and qualitative support infrastructure for all phases of cancer research; from study development and design to data collection, ongoing monitoring, and final analysis.

Max Amount and Period: N/A

Eligibility: Must be a Siteman Cancer Center member.

Due Date: Rolling

Additional Details

RFP Snapshot: The WUSTL Center for Drug Discovery offer the CDD Match Grant15 and Grant25 programs.

Match Grant15 is to advance translational small-molecule drug discovery research at Washington University. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in vivopharmacokinetics for proof-of-concept in vivo pharmacology studies, intellectual property (patent) filing, and drug development.

Match Grant25 is a follow-on award program meant only for those investigators who have successfully completed and met the objectives of a Match Grant15 (or the original CDD MicroGrant) award and request additional match funds to further advance the discovery research project. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in vivo pharmacokinetics for proof-of-concept in vivo pharmacology studies, intellectual property (patent) filing, and drug development.

Max Amount and Period:

Match Grant15 – $7,500 from CDD

Match Grant25 – $12,000 from CDD

Eligibility:

Match Grant15 – open to investigators with a faculty appointment at Washington University

Match Grant25 – open only to WashU faculty who have successfully completed a Match Grant15 (or CDD MicroGrant) and submitted a final research report.

Due Date: Rolling

Additional Details

RFP Snapshot: The purpose of the awards is to advance initial discovery pilots for Precision Health ICTS investigators. Proposals are not for developed projects but are to fund developmental or early stage work, including pilot data collection and analysis, in preparation for submission of future external funding.

Max Amount and Period: $25,000 for 1 year

Eligibility: Applicants must be full time faculty (instructor level or above) at Washington University in St. Louis or an ICTS partner institution. Applicant must be a member of the ICTS.

Due Date: Rolling

Additional Details

RFP Snapshot: The Just-In-Time (JIT) Core Usage Funding Program is designed to provide quick access to funding to use any of the JIT Cores (pdf) for research advancing medical knowledge that can improve human health. Siteman Cancer Center will co-sponsor cancer-focused proposals.

Max Amount and Period: Varies

Eligibility: Applicant must be a registered member of the ICTS and hold a faculty level appointment at WUSTL or an ICTS partner institution.

Due Date: Rolling

Additional Details

RFP Snapshot: The intent of the EDS Accelerator Award is to support the commercialization of an ongoing cancer research project and to validate and de-risk technologies. Proposals should address key experiments required to move findings toward commercialization, that do not easily fit into traditional funding mechanisms. This mechanism is not designed to initiate new projects or develop new directions for an ongoing project. The proposal should be commercially driven with the PI having a plan to license the technology, either to an established company or a start-up if the experiment(s) are successful.

Max Amount and Period: $75,000 for 1 year

Eligibility: Applicants must be current or former ACS grantees (including IRG pilot grant awardees) or former ACS postdoctoral fellows. Applicants must have a full-time faculty appointment and may be at any career stage. Applicant should be motivated to commercialize their technology.

Due Date: Rolling

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: Pilot Accelerator Awards support investigators who propose potentially transformative ideas without extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for such “high-risk, high-reward” projects are important to establish proof-of-concept, which may then leverage additional funding through more traditional avenues.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applicants must have an academic non-profit or industrial research appointment and will be considered on a case-by-case basis.

Due Date: Rolling

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: Young Investigator Accelerator Awards aim to attract early career faculty with original ideas into the field of colorectal cancer research, thereby recruiting and supporting the next generation of CRC research leaders. Awardees will be provided funding to accomplish innovative and original, preclinical, translational, and/or early clinical research projects.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applicants must be within the first five years of their first independent, full-time academic or nonprofit faculty appointment.

Due Date: Rolling

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The Team Science Accelerator Award will support team science, including public-private partnerships, that will accelerate CRC research to curative science. Research proposals will be considered that accelerate new therapeutic and technology innovations from bench to bedside and address unmet clinical needs.

Max Amount and Period: $500,000 over 2 years

Eligibility: Principal Investigator of a Team Accelerator Award proposal must be a senior investigator with more than five years of active research in colorectal cancer. Research teams may be from a single institution or multiple institutions. Research teams may include both academic, non-profit and industry (biotech/pharma) researchers.

Due Date: Rolling

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: Senior Investigator Accelerator Awards will fund potentially transformative ideas that will accelerate the translation of new therapies and technologies to the bedside by the end of the proposed research. Collaborations are highly encouraged.

Max Amount and Period: $500,000 over 2 years

Eligibility: Principal Investigator must be a senior researcher, past the initial five years of their first academic or non-profit faculty appointment. Key collaborators are not required to qualify as a senior researcher.

Due Date: Rolling

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: Pioneering Ideas: Exploring the Future to Build a Culture of Health welcomes proposals that are primed to influence health equity in the future. We seek ideas that address any of RWJF’s Pioneering Ideas for an Equitable Future team’s four current areas of focus described below: 1) Future of Evidence; 2) Future of Social Interaction; 3) Future of Food; and 4) Future of Work. Additionally, under Open Exploration, also described below, this call for proposals seeks ideas that might fall outside of these four focus areas but which offer unique approaches to advancing health equity and our progress toward a Culture of Health.

Max Amount and Period: No limit for 3 years, but budget must be reasonably supported by scope of project.

Eligibility: Applicant organizations must be based in the US or its territories. Preference will be given to applicant organizations that are either institutes of higher education, public entities, or nonprofits that are tax exempt under Section 501(c)(3) of the Internal Revenue Code.

Due Date: Rolling

Additional Details

RFP Snapshot: This opportunity is meant to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote the dissemination and implementation of evidence-based interventions among relevant communities are encouraged.

Max Amount and Period: $100,000 over 2 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

Due Date: June 16, 2025 at 5pm CST

Additional Details

RFP Snapshot: This opportunity is meant to support the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).

Max Amount and Period: $275,000 over 2 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

Due Date: June 16, 2025 at 5pm CST

Additional Details

RFP Snapshot: The purpose of the ‘A’ Award Grant is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to early career scientists who want to establish a career in pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of a future commitment to pediatric cancer investigation as well as institutional support for the career development of the investigator are critical components of a successful application. A mentor is required, and a career development plan must be included.

Max Amount and Period: $800,000 over 4 years

Eligibility: Applicants must have an MD, PhD or MD/PhD (DO, MBBS or equivalent) and be within 5 years of their first faculty appointment as an Assistant Professor at the time of submission. MD and MD/PhDs must be within ten years of their terminal research degree or end of post-graduate clinical training (whichever date is later). PhDs must be within ten years of their terminal research degree. If still at the Instructor level, the applicant must have a firm commitment from the Department Chair/Division Chief at the time of grant submission for an Assistant Professor position within one year of receiving the award. A minimum of 75% of the applicant’s time during the ‘A’ Award period must be allocated as non-clinical protected time for all research activities. A mentor(s) must be identified and must be in the applicant’s home institution. A co-mentor whose research expertise is aligned with the application could be added from an outside institution. Applicants cannot be the Principal Investigator (PI) of a K99/R00 or other independent, nationally competitive award (e.g., R01 or equivalent, P or U award) that has been funded or recommended for funding (i.e., will be funded) any time before the ‘A’ Award grant start date. Applicants may have mentored-career development grants (such as K01, K08, K23, K25) or mentored-research grants (such as ACS-Clinician Scientist Development Grant; DoD Physician Research Award) from other funding sources during the ‘A’ Award period, but there must be clear documentation of how scientific and budgetary overlap will be avoided. Applicants currently holding an ALSF Young Investigator (YI) Grant may apply. If the ‘A’ Award is given, it would supersede the YI grant if there is an overlap in the funding periods.

Due Date: June 16, 2025 at 7pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant.

Max Amount and Period: $275,000 over 2 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

Due Date: June 16, 2025 at 5pm CST

Additional Details

RFP Snapshot: The Robert A. Winn Excellence in Clinical Trials: Clinical Investigator Leadership Award powered by Conquer Cancer’s EveryGrant® (Winn CILA-Onc) is a three-year career and leadership development program designed to provide oncology graduates of the Winn Career Development Award (Winn CDA) program with advanced clinical trials knowledge, leadership skills, mentorship and sponsorship to succeed as independent clinical researchers, team members, and leaders.

Max Amount and Period: The program will provide salary support for the participants during their award term, support for the NCTN cooperative groups, and other training-related costs.

Eligibility: Applicants must be a current or immediate past Robert A. Winn Career Development Award Scholar who has or will complete the Winn CDA term by January 15, 2026. Completed an oncology subspeciality training. Be employed by an institution that is a current/active member of an NCI National Clinical Trials Network. Be able to commit at least 30% of full- time effort in during the award period, as confirmed in an institutional Letter of Support.

Due Date: June 16, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The RFA is for existing or new drug development for an early phase clinical trial or for a late-stage research project ready for IND-enabling studies that may advance our understanding of gastroesophageal cancer and lead us to impacting patient care. Completion date should be between 1 to 3 years. Grants may be supported in full or partially based on the aims of the project, novelty and feasibility.

Max Amount and Period: $2M for 1-3 years

Eligibility: We encourage interdisciplinary collaborations and welcome proposals from independent investigators at all career stages, especially those new to the field of upper GI cancers. Proposals that include a clinical trial will require a clinical trial budget, and commitment for the study drug. Research projects must not be funded currently under a separate mechanism.

Due Date: Letter of Intent Due: June 16, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The purpose of this grantmaking program is to bring together researchers across the world and provide funds for ovarian cancer research using Artificial Intelligence (AI) technologies, such as machine learning. We believe this type of collaboration will allow for sharing of knowledge, expertise, innovation and resources, spark new ideas to achieve groundbreaking results to better the lives of ovarian cancer survivors, and accelerate scientific research globally.

Max Amount and Period: $1M over 3 years

Eligibility: Applicant teams must consist of at least 4 lead senior researchers with representation from at least the following countries – United States, United Kingdom, Canada, and Australia. Teams must include involvement of an AI specialist or experienced AI researcher to ensure robust methodology and innovation. It is strongly preferred that teams include at least one member who is a clinician, MD/DO/PA, etc., or has relevant clinical experience, to ensure clinical translatability.

Due Date: Letter of Intent Due: June 18, 2025 at 4pm CST

Application Assistance: Washington University faculty may reach out to Julie Potter Najem in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: Core grants funding early phase clinical trials for cancers of all types at renowned institutions around the world. These grants are typically 2-5 years in duration with award amounts from $200,000 to $1.5 million.

Max Amount and Period: $200,000 to $1.5M over 2 to 5 years

Eligibility: An investigator-initiated application from any academic, non-profit, or for-profit organization, institution, or medical center is welcome. An investigator who is ready to conduct a novel, clinical trial in cancer research — one which will have an immediate impact on cancer patients — may apply for funding on behalf of such organization, institution, or medical center. The principal investigator will be required to submit a biosketch illustrating their work as a clinician and/or researcher.

Due Date: Letter of Intent Due: June 20, 2025 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The TRTH program includes an intensive week-long course held in the spring and year-long mentoring interaction with experts in the field. Mornings are dedicated to research seminar-style interactive sessions on translational and basic science research methodology, cutting-edge technology, and career development. Afternoons are devoted to small group sessions in which participants meet with their TRTH mentors, peers, and faculty to refine their individual research proposals and hone their scientific presentation and communication skills.

Max Amount and Period: Week-long course held in spring, year-long mentoring

Eligibility: Applicants must be a trainee or junior faculty and hold an MD and/or PhD or biomedical PhD or pharmacy PharmD degree (or equivalents) in basic and translation research in classical or malignant hematology. MDs must be within 12 years of post-graduation and PhDs must have less than 8 years of postdoc experience after graduation. MD/PhDs must be within 12 years of MD graduation.

Due Date: Letter of Intent Due: June 26, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: Our overall goal is to improve cancer patients’ treatment options and quality of life by funding clinical studies focused on therapy optimization, disease and treatment burden, and early detection and intervention. We fund phase I to phase III interventional clinical trials.

Max Amount and Period: $500,000 over 5 years

Eligibility: Both early-career and established investigators are encouraged to apply. An applicant must be an independent investigator with demonstrated experience and training to be able to organize, manage, and implement the clinical trial to meet milestones and timelines, and to protect the rights and welfare of the human subject participant. Clinical trials must be interventional, early to late stage (Phase 1, 2, and 3); they may include secondary non-clinical endpoints. Applicants must have patient partner involvement.

Due Date: Letter of Intent Due: June 29, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This opportunity will accept applications studying bone marrow failure and advancing the understanding, prevention and treatment of bone marrow disorders in both pediatric and adult populations. The projects may be basic research, translational research, preclinical research (e.g. drug development), early-stage clinical research, and health services research/epidemiology. The project must represent independent research conducted by the applicant.

Max Amount and Period: $60,000 over 2 years

Eligibility: Preference will be given to new investigators who propose a project that will contribute toward their professional development in bone marrow failure disease research. New investigators are post-doctoral fellows, instructors, and those who have been assistant professors for fewer than five (5) years.

Due Date: Letter of Intent Due: June 30, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: These grants are intended to provide a deeper understanding of the mechanisms of action of this novel anti-cancer treatment modality and to accelerate the development of new treatment strategies to advance therapeutic options for cancer. The research proposed for funding may be basic or translational in nature; however, studies promoting the transition of in vitro work into in vivo systems, combination therapies involving TTFields, or translational projects bringing treatments involving TTFields into the clinic will be prioritized. Research proposals must incorporate use of the Inovitro® system into the experimental design.

Max Amount and Period: $300,000 over 3 years

Eligibility: Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. At the start of the grant term on December 1, 2025, applicants must hold a faculty position with the the title of Instructo, Assistant Professor, Research Assistant Professor, or equivalent. Must have received first faculty position with the title of assistant professor, instructor, research assistant, or the equivalent within the past 6 years (before December 1, 2025). Must be AACR Active member.

Due Date: June 30, 2025 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: These grants are intended to provide a deeper understanding of the mechanisms of action of this novel anti-cancer treatment modality and to accelerate the development of new treatment strategies to advance therapeutic options for cancer. The research proposed for funding may be basic or translational in nature; however, studies promoting the transition of in vitro work into in vivo systems, combination therapies involving TTFields, or translational projects bringing treatments involving TTFields into the clinic will be prioritized. The Inovitro® system (which will be provided by Novocure, if needed), must be included in the experimental design. Training on the use of Inovitro® system will be provided by Novocure, if needed.

Max Amount and Period: $350,000 over 3 years

Eligibility: Applicants must be AACR Active members who are independent investigators and have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Current AACR grantees may apply only if their current grant ends before the start of the grant term of this funding opportunity (December 1, 2025). Current and past recipients of an AACR-Novocure Tumor Treating Fields Research Grants are not eligible to apply. Collaborators or other participants of an active AACR Novocure grant (at the time of application deadline) are also not eligible to apply.

Due Date: June 30, 2025 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The goal of this RFP is to provide initial support to identify new therapeutic modalities including small molecules, antibodies, protein degraders, and cell therapies against validated melanoma targets, specifically in acral and/or uveal melanoma.

Max Amount and Period: $250,000 over 2 years

Eligibility: Principal Investigators (PIs) must hold a full-time faculty appointment at the level of Assistant Professor (or equivalent) or above.

Due Date: June 30, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The goal of this Next Step RFP is to provide seed funding to support the characterization of established preclinical models (eg, cell lines, patient-derived xenografts, organoids, and animal models) of rare melanomas.

Max Amount and Period: $200,000 over 2 years

Eligibility: Principal Investigators (PIs) must hold a full-time faculty appointment at the level of Assistant Professor (or equivalent) or above.

Due Date: June 30, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The aim of this award is to fund translation studies that support therapeutic development, biomarker research, or any other projects that will have the ability to impact pediatric cancer patients within several years.

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicants must have an MD, PhD, or MD/PhD or equivalent. Post doctoral researchers are eligible to apply. Applicants must have a demonstrated track record of pediatric cancer research. Research must be original, novel and focus on pediatric liquid or solid cancer. Applicants MAY be involved in other research grants, but there must be clear documentation of mechanisms to avoid scientific and/or budgetary overlap.

Due Date: Letter of Intent Due: July 1, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The aim of this award is to fund early-stage pediatric leukemia research to support the basic science discoveries that will translate to long-term improvements for pediatric leukemia patients.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applicants must have an MD, PhD, or MD/PhD or equivalent and be appointed as faculty (or equivalent) at an academic institution. Applicants must have a demonstrated track record of pediatric cancer research. Research must be original, novel and focus on pediatric leukemia. Applicants MAY be involved in other research grants, but there must be clear documentation of mechanisms to avoid scientific and/or budgetary overlap.

Due Date: Letter of Intent Due: July 1, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The aim of this award is to fund basic science in pediatric leukemias. Apply for the John Voight Memorial Leukemia Research Grant if your project is geared toward translational science in leukemias, with an emphasis on AML.

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicants must have an MD, PhD, or MD/PhD or equivalent and be appointed as faculty (or equivalent) at an academic institution. Applicants must have a demonstrated track record of pediatric cancer research. Research must be original, novel and focus on pediatric leukemia. Applicants MAY be involved in other research grants, but there must be clear documentation of mechanisms to avoid scientific and/or budgetary overlap.

Due Date: Letter of Intent Due: July 1, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This grant is meant to support new areas of investigation leading to future applications for larger grants from private or public sources. Therefore, it is important for the application to present both well-planned research and a clear plan on how the results from the proposed work will lead to future funding.

Max Amount and Period: $100,000 over 2 years

Eligibility: Principal Investigators (PIs) may be a Ph.D. or M.D. and must hold a faculty position (or equivalent) at an academic institution or medical center in the United States. Postdocs may not serve as a PI. The application may contain basic, translational, or clinical research to investigate any form of pediatric brain cancer. The work must represent a new line of research that has not received significant private or public (e.g. NIH R01) funding in the past.

Due Date: July 1, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.

Max Amount and Period:
• Stage 1: $400,000 over 2 years
• Stage 2: $400,000 over 2 additional years

Eligibility: The applicant must have received an MD, DO, PhD, or MD/PhD degree(s) from an accredited institution. Basic and translational/clinical projects will be considered. Applicants with a background in multiple disciplines are especially encouraged to apply. Applicants are expected to commit a minimum of 80% of their time to conducting research. Applicants must demonstrate that they have access to the resources and infrastructure necessary to conduct the proposed research. The department must guarantee the Investigator is conducting the proposed research independently. Applicants must belong to one of the following categories:
• Tenure-track Assistant Professors within the first five (5) years of obtaining their initial tenure-track Assistant Professor position (Cut-off date: July 1, 2020);
• Clinical Instructors and Senior Clinical Fellows (in the final year of their sub-specialty training) holding an MD, MD/PhD, DO who are pursuing a period of independent research before taking a tenure-track faculty position. Such individuals must have an exceptional record of research accomplishment, dedicated laboratory space and the support of their institution;
• Distinguished Fellows with an exceptional record of research accomplishment identified by their institution to pursue an independent research program and who have dedicated laboratory space. These candidates are markedly distinct from traditional postdoctoral fellows. Examples: Whitehead Fellows, UCSF Fellows, Cold Spring Harbor Fellows.

Due Date: July 1, 2025 at 3PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

WUSTL may nominate ONE (1) person to move on to the full application stage.

Additional Details

RFP Snapshot: This award supports researchers in the early stages of their faculty careers by providing support for up to 3 years of “protected time” for research career development under the guidance of a Mentor Committee. Komen seeks to support those who will emerge as the next key leaders in the fight against breast cancer.

Max Amount and Period: $450,000 over 3 years

Eligibility: Applicants must hold a full-time faculty appointment (for no more than 6 years) or have a formal offer letter that confirms position and start date by full application due date (October 2, 2025). Must be able to devote at least 75% effort to breast cancer research. May not currently be or have been a Principal Investigator on an existing NIH R01 grant or their equivalent as of the date of Award Notification (on or around April 15, 2026).

Due Date: WUSTL INTERNAL DEADLINE: July 1, 2025 at 11:59PM CST

WUSTL may nominate TWO (2) applicant teams to move on to the full application stage.

Additional Details

RFP Snapshot: The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.

Max Amount and Period: $3M over 3 years

Eligibility: 1st submission may be any cancer type. A 2nd submission must focus on one of the following types: Upper GI, glioblastoma, TNBC, or Pancreatic Cancer. Applicants must have an independent faculty appointment (tenure-track or equivalent) at a non-profit academic/research institution. Teams must be composed of one PI and 2-8 co-PIs (see “Team Roles” section for definitions). Inter-institutional collaborations are permitted and encouraged.

Due Date: WUSTL INTERNAL DEADLINE: July 1, 2025 at 11:59PM CST

Additional Details

RFP Snapshot: The aim of this program is to encourage physician-scientists who have shown significant promise toward becoming independent investigators by successfully competing for career development awards from federal and other funding sources, and to promote their pursuit of additional urologic research education and training.

Max Amount and Period: $200,000 over 5 years

Eligibility: Applicants must be board-certified or -eligible urologists or be participating in a training program to obtain board certification in urology. Applicants must hold an extramural, peer-reviewed career development award. Examples include K07, K08, or K23 awards from the National Institutes of Health, or career development-type grants from the Department of Veterans Affairs, Department of Defense, American Cancer Society, and others. Have at least two full years remaining on the period of performance for the career development award with not less than 50% protected time for research.

Due Date: July 7, 2025 at 4pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

WUSTL may nominate ONE (1) person to move on to the full application stage.

Additional Details

RFP Snapshot: The Rita Allen Foundation Scholars Program is designed to support young independent investigators who are leaders in biomedical science and whose research focus is on areas that are of global concern in the fields of cancer, neuroscience, and immunology.

Max Amount and Period: $550,000 over 5 years

Eligibility: Applicants must be in the early stages of their careers; most likely, this will mean a recent appointment at a faculty level. They must have completed their training and provided persuasive evidence of distinguished achievement or have shown extraordinary promise in research in one of the relevant fields.

Due Date: WUSTL INTERNAL DEADLINE: July 15, 2025 at 11:59PM CST

Additional Details

RFP Snapshot: This is a quality improvement grant opportunity to improve the patient experience in bladder cancer care, specifically focusing on the multi-disciplinary management of care. This grant program will support innovative projects to improve the quality of bladder cancer care in diverse clinical settings in the United States.

Max Amount and Period: $250,000 over 2 years

Eligibility: The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/PI’s grant/research coordinator).

Due Date: July 23, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This grant mechanism aims to foster innovation and advance the translation of promising ideas in metastatic breast cancer research, including the exploration of potential therapeutic targets and biomarkers. By supporting efforts to bridge basic science with emerging treatment strategies, the grant also aims to foster the development of the next generation of cancer researchers.

Max Amount and Period: $50,000 for 1 year

Eligibility: Applicant must have a PhD, MD, MD/PhD, or equivalent and be an independent investigator.

Due Date: July 24, 2025 at Noon CST

Application Assistance: Washington University faculty may reach out to Julie Potter Najem in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This competitive grant program seeks to support research studies that focus on generating evidence on the use of elranatamab in multiple myeloma in the real world setting.

Max Amount and Period: $200,000

Eligibility: The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).

Due Date: July 23, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: Concern Foundation for Cancer Research supports the development of the next generation of cancer researchers and thus promotes progress in understanding cancer biology and improved approaches to cancer.

Max Amount and Period: $200,000 over 2 years

Eligibility: Eligible applicants are independent investigators who are at the start of their scientific career (i.e., junior faculty) and are at the level of Assistant Professor (or equivalent, with explanation). This means you have been independent in terms of lab space, budget usage, directing your own research, publishing, etc. for between 1 and 7 years. Successful proposals are usually from investigators who have been in their independent position and directing their own research program for more than one year. An applicant who is a PI with an existing R01 or equivalent is not eligible.

Due Date: Letter of Intent Due: July 25, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious disease research (not including HIV/AIDS).

Max Amount and Period: $1.15M over 5 years

Eligibility: Applications may be submitted by an eligible foreign institution in a LMIC with a collaborating U.S. institution or by an eligible U.S. institution that demonstrates ongoing collaborations with a LMIC institution named in the application. In many cases, it is anticipated that the proposed program will complement other ongoing research training occurring at the applicant institution and that a substantial number of program faculty will have active research projects in which participating trainees may gain relevant experiences consistent with their research interests and goals. The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. U.S. applicants must identify at least one LMIC scientist with expertise in the infectious disease focus area of the proposed research training program from the proposed collaborating U.S./LMIC institution as the main collaborator for coordinating training program activities at that site.

Due Date: August 6, 2025 at 5pm CST

Additional Details

RFP Snapshot: The goal of this award is to address the critical shortage of scientists focusing on pediatric cancer by recruiting outstanding young minds committed to tackling these issues. The goal is to fund individuals who propose innovative approaches in either basic or clinical research with the potential to significantly impact the prevention, diagnosis, or treatment of one or more pediatric cancers. Candidates must apply for the Damon Runyon-St. Jude Pediatric Cancer Research Fellowship under the guidance of a Sponsor, a scientist (tenured, tenure-track, or equivalent position) capable of providing mentorship to the Fellow.

Max Amount and Period: $300,000 over 4 years

Eligibility: Applicants must have completed one or more of the following degrees or its equivalent: MD, PhD, MD/PhD, DDS, DVM, DO.

Level 1 applicants: Basic and physician-scientists must have received their degrees no more than 36 months prior to the application deadline date. Applicants must not have been in their Sponsors’ labs for more than two years prior to the application deadline date and are expected to devote 100% of their time to Damon Runyon-supported research activities.

Level 2 applicants: Physician-scientist applicants (MD, MD/PhD, DDS, DVM, DO or the equivalent) must have completed their residencies and clinical training, must be board eligible in the United States at the start date of the Damon Runyon-St. Jude Pediatric Cancer Research Fellowship Award, and be able to devote at least 80% of their time to Damon Runyon-supported research activities. Applicants must apply within two years of ending their clinical fellowship and anytime prior to their initial assistant professorship appointment (or equivalent). Postdoctoral fellows, clinical fellows, and clinical instructors are eligible to apply. Applicants cannot be in their Sponsor’s lab more than four years prior to the application deadline date.

Candidates who have already accepted a postdoctoral research fellowship award are not eligible. Candidates may hold a T32 at the time of application, but not concurrently with the Damon Runyon-St. Jude Pediatric Cancer Research Fellowship Award.

Foreign candidates may apply to do their research only in the United States.

Due Date: August 15, 2025 at 3pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This funding opportunity is meant to fund investigator-initiated, proof of concept, Phase I or Phase IIA clinical trials to validate artificial intelligence (AI)-driven repurposing opportunities in any unsolved disease, where the therapies supported by AI models are already approved. Eligible clinical repurposing trials must include AI-generated data as part of the preclinical support for the trial.

Max Amount and Period: $100,000 for 1 year

Eligibility: Projects must either be led by a previously funded investigator or by an early-stage investigator who has received little or no extramural research funding to date. PIs who have not received extramural funding previously and/or who do not currently have their own lab should include a Letter of Support from a funded, senior researcher who will act as a mentor for the proposed research and the investigator. Projects should not yet have funding or already have funding from another source, when funding from CWR will help improve the chances of success of the trial and/or help speed patient impact

Due Date: Letter of Intent Due: August 25, 2025 at 5:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The Elsa U. Pardee Foundation funds research directed toward identifying new treatments or cures for cancer. The Foundation funds projects for a one-year period which will allow the establishment of capabilities of new cancer researchers or new cancer approaches by established cancer researchers. It is anticipated that this early-stage funding by the Foundation may lead to subsequent and expanded support using government agency funding.

Max Amount and Period: No limit for 1 year

Eligibility: Priority is given to researchers at non-profit institutions in the United States who are new to the field of cancer research, or to established research investigators examining new approaches to cancer cure. Post-docs who are on the tenure track and have a tenured mentor are eligible.

Due Date: August 31, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: ACS Professor awards are primarily honorific awards for individuals who have made seminal contributions in cancer research. These notable cancer research achievements could have been fundamental, preclinical, clinical, psychosocial, behavioral, health policy and/or epidemiologic in focus. Commitment and success in scientific mentoring and leadership as well as community engagement are also carefully considered.

Max Amount and Period: $400,000 over 5 years

Eligibility: Applicants must be at the rank of full professor and have made, and will likely continue to make, impactful contributions to change the direction of cancer research.

Due Date: Letter of Intent Due: September 1, 2025 at 4pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This is meant to support the hematology-focused careers of ASH members who are trainees or early-career investigators based in countries other than the United States or Canada. If you are not a US or Canadian citizen and are temporarily training in the US or Canada, you can apply to the Global Research Award only if you have an academic position at an institution in your country for you to return to once your studies complete in the US or Canada.

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicants must be based in a country other than the US or Canada, have a MD, PhD, or MD/PhD and be within 16 years of graduation date.

Due Date: Letter of Intent Due: September 2, 2025 at 10:59pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This mechanism is meant to fund cutting-edge childhood cancer research – basic, translational, or clinical – which may lead towards cures and better treatments for childhood cancers

Max Amount and Period: $150,000 over 2 years

Eligibility: Applicants must have a M.D., D.O., Ph.D, or PharmD degree. Applicants may be Assistant, Associate or Professor level investigators. Applications will be considered from instructors who have a minimum of a two-year commitment from an accredited academic institution.

Due Date: Letter of Intent Due: September 3, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The Clinical Investigator Career Development Award (CDA) Program is designed to support physician investigators at the level of advanced fellow or junior faculty member who will contribute to the development of new lymphoma therapies and diagnostic tools.

Max Amount and Period: $375,000 over 3 years

Eligibility: Applicants must have no more than 6 years of experience beyond completion of their fellowship or postdoc training. Applicants must be licensed clinical physicians. Applicant must be an advanced fellow or junior faculty member with at least 2 years (24 months) of fellowship or postdoctoral training and no greater than six years of experience beyond completion of his/her fellowship or postdoctoral training. The applicant must spend 35 to 50 percent of their time in research. This time should be free of major patient care, teaching or administrative responsibilities. The CDA recipient will not be permitted to hold any other career development award during the award period of the LRF grant.

Due Date: September 4, 2025 at 4pm CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This opportunity is for applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives:

1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and

2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and settings by applying current aging science approaches.

Max Amount and Period: No limit for 5 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

Due Date: September 7, 2025 at 5pm CST

Additional Details

RFP Snapshot: This opportunity is for applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives:

1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and

2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and settings by applying current aging science approaches.

Max Amount and Period: $275,000 over 2 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

Due Date: September 7, 2025 at 5pm CST

Additional Details

RFP Snapshot: This funding opportunity is part of LLS’s Equity in Access Research Program, designed to generate evidence that will guide changes in healthcare policy and practice to ensure that all patients with and survivors of a blood cancer have the ability to access and utilize optimal treatment, care, and resources that can improve their quality of life and outcomes, from diagnosis through survivorship.

Max Amount and Period: $2.5M over 5 years

Eligibility: Applicants may be at any stage of their careers. However, if the PI is an early-career investigator, a more experiences co-PI is required. Multi-disciplinary teams are strongly encouraged. Study teams must include at least one stakeholder (e.g., community oncologists, patients, clinical research staff, patient navigators).Study teams may also include one or two Co-Principal Investigator(s) and multiple Co-Investigators.

Due Date: September 11, 2025 at 2pm CST

Pre-Application Webinar: June 18, 2025 at 11am CST – REGISTER NOW!

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The objective of this AGA Research Foundation Pilot Research Award is to provide funds to early career investigators to help establish their research careers or to support projects that represent new research directions for established investigators.

Max Amount and Period: $40,000 for 1 year

Eligibility: Applicants must hold an MD, PhD, or equivalent degree and have a full-time faculty position. AGA membership is required.

Due Date: September 18, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The objective of this AGA Research Foundation award is to provide supplemental funding to early career investigators who have existing career development awards and are conducting research relevant to the pathogenesis, prevention, diagnosis or treatment of digestive cancer.

Max Amount and Period: $40,000 for 1 year

Eligibility: Applicants must be early-career and hold an MD (no more than 7 years elapsed since clinical training), PhD (no more than 7 years elapsed since PhD degree), or equivalent degree and have a full-time faculty position. AGA membership is required. Applicants MUST hold an NIH K series or other federal or non-federal career development award of at least four years’ duration. You must have at least one year remaining on the award on April 1, 2026. Applicants may NOT hold an R01 or equivalent, such as a VA Merit Award.

Due Date: September 18, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The objective of this AGA Research Foundation award is to support an established investigator in the field of gastric cancer research working to enhance our fundamental understanding of gastric cancer pathobiology or approaches to prevent, treat or cure gastric cancer.

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicants must be established researcher and hold an MD (for more than 7 years since clinical training completion), PhD (for more than 7 years since PhD degree), or equivalent degree and have a full-time faculty position. AGA membership is required.

Due Date: September 18, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The Therapeutic Catalyst is meant to accelerate the translation of laboratory discoveries into novel cancer therapeutics. This opportunity aims to de-risk early projects to facilitate further drug discovery research, funding, or partnering. Cancer Research UK is seeking projects with strong therapeutic potential to deliver patient benefit. They invite applications for early drug discovery proposals from across all cancer indications and modalities.

Max Amount and Period: £250,000 over 18 months (roughly $340,000)

Eligibility: Applicants must have their own lab and be based at any university or research institute worldwide.

Due Date: Letter of Intent Due: October 3, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This opportunity is designed to address the needs of patients and the medical community. It aims to fund evidence-based interventional clinical trials in supportive care, specifically by early-career investigators. The RFA invites proposals on hypothesis-driven interventional clinical trials within supportive care. These trials aim to improve cancer patients’ quality of life through prevention and management of the adverse effects of cancer and its treatment. Study outcomes should include well-validated clinical and patient-reported outcomes. Phase I to II clinical trials are encouraged. Other well-designed studies, such as comparative effectiveness trials, may be considered. Survivorship clinical trials or interventions, including dietary or natural products, are not eligible for this RFP.

Max Amount and Period: $245,000 over 4 years

Eligibility: Applicants should be in their first to third year of a full-time, primary faculty appointment in a clinical department. Applicants need to secure a mentor from their institution willing to support them for the duration of their trial. The mentor must provide a letter of support proving a prior working relationship.

Due Date: Letter of Intent Due: October 30, 2025

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.